IP Verse

Treatment Of Solid Tumours With Rapamycin Derivatives - EP2269603

The patent EP2269603 was granted to Novartis on May 20, 2015. The application was originally filed on Feb 18, 2002 under application number EP10174983A. The patent is currently recorded with a legal status of "Revoked".

EP2269603

NOVARTIS
Application Number
EP10174983A
Filing Date
Feb 18, 2002
Status
Revoked
Nov 15, 2019
Grant Date
May 20, 2015
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ZENTIVA FRANCEJul 8, 2019BIRD & BIRDINTERVENTION ADMISSIBLE
ACTAVIS PTC EHFFeb 22, 2016SCHIENERADMISSIBLE
INTAS PHARMACEUTICALSFeb 22, 2016PLOUGMANN VINGTOFTADMISSIBLE
STADA ARZNEIMITTELFeb 22, 2016HAMM & WITTKOPPADMISSIBLE
SYNTHONFeb 22, 2016PRINSADMISSIBLE
WITTKOPPFeb 22, 2016HAMM & WITTKOPPADMISSIBLE
ETHYPHARMFeb 19, 2016ALLABADMISSIBLE
GENERICS UKFeb 19, 2016ELKINGTON AND FIFEADMISSIBLE
TEVA PHARMACEUTICALSFeb 18, 2016SCHIENERADMISSIBLE

Patent Citations (54) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0296110
DESCRIPTIONEP0520722
DESCRIPTIONEP0564409
DESCRIPTIONEP0566226
DESCRIPTIONEP0769947
DESCRIPTIONEP0787722
DESCRIPTIONEP0837063
DESCRIPTIONGB2177700
DESCRIPTIONUS4100274
DESCRIPTIONUS4636505
DESCRIPTIONUS4659516
DESCRIPTIONUS5010099
DESCRIPTIONUS5362718
DESCRIPTIONUS5747498
DESCRIPTIONUS5843901
DESCRIPTIONWO0009495
DESCRIPTIONWO0027819
DESCRIPTIONWO0027820
DESCRIPTIONWO0037502
DESCRIPTIONWO0059509
DESCRIPTIONWO9409010
DESCRIPTIONWO9410202
DESCRIPTIONWO9503283
DESCRIPTIONWO9516691
DESCRIPTIONWO9630347
DESCRIPTIONWO9633980
DESCRIPTIONWO9641807
DESCRIPTIONWO9702266
DESCRIPTIONWO9730034
DESCRIPTIONWO9738983
DESCRIPTIONWO9749688
DESCRIPTIONWO9810767
DESCRIPTIONWO9811223
DESCRIPTIONWO9835958
DESCRIPTIONWO9903854
DESCRIPTIONWO9917804
EXAMINATIONWO02080975
EXAMINATIONWO9706793
OPPOSITIONGB2177700
OPPOSITIONWO0069467
OPPOSITIONWO0145740
OPPOSITIONWO9409010
OPPOSITIONWO9706793
OPPOSITIONWO9747317
SEARCHEP1074263
SEARCHUS5066493
SEARCHUS5206018
SEARCHWO0187372
SEARCHWO0213802
SEARCHWO9409010
SEARCHWO9516691
SEARCHWO9641807
SEARCHWO9747317
SEARCHWO9811908

Non-Patent Literature (NPL) Citations (18) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CLARK, BREAST CANCER RESEARCH TREATMENT, (1997), vol. 46, page 255-
DESCRIPTION- F. YUAN ET AL., PROC. NATL. ACAD. SCI. USA, (199612), vol. 93, pages 14765 - 14770-
DESCRIPTION- J. MORDENTI ET AL., TOXICOLOGIC PATHOLOGY, (1999), vol. 27, no. 1, pages 14 - 21-
DESCRIPTION- M. PREWETT ET AL., CANCER RESEARCH, (1999), vol. 59, pages 5209 - 5218-
DESCRIPTION- M. S. O'REILLY ET AL., CELL, (1994), vol. 79, pages 315 - 328-
DESCRIPTION- M. S. O'REILLY ET AL., CELL, (1997), vol. 88, pages 277 - 285-
DESCRIPTION- Z. ZHU ET AL., CANCER RES., (1998), vol. 58, pages 3209 - 3214-
EXAMINATION- "Novartis drug Afinitor(R) helps women with advanced breast cancer live significantly longer without their disease progressing", ONKOLOGIE, CZ, (20110101), vol. 5, no. 5, ISSN 1802-4475, page 311, XP009181575-
EXAMINATION- TSUCHIYA N ET AL, "EFFECTS OF FADROZOLE AND LEUPRORELIN ACETATE ON AROMATASE ACTIVITY AND CELL PROLIFERATION IN A HUMAN BREAST CANCER CELL LINE (SK-BR-3)", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, CHURCHILL LIVINGSTONE JAPAN, TOKYO, GB, (20000101), vol. 5, ISSN 1341-9625, pages 183 - 187, XP001069645-
EXAMINATION- M. Harding ET AL, "Estrogen and progesterone receptors in ovarian cancer", Cancer, (19900201), vol. 65, no. 3, doi:10.1002/1097-0142(19900201)65:3<486::AID-CNCR2820650319>3.0.CO;2-C, ISSN 0008-543X, pages 486 - 491, XP055136080
EXAMINATION- KLEINE W ET AL, "Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 38, no. 1, doi:10.1016/0090-8258(90)90012-A, ISSN 0090-8258, (19900701), pages 59 - 65, (19900701), XP026239081
EXAMINATION- Naofumi Nagasue ET AL, "Clinicopathologic Comparisons Between Estrogen Receptor-positive and -negative Hepatocellular Carcinomas", Annals of Surgery, (19900801), vol. 212, no. 2, doi:10.1097/00000658-199008000-00006, ISSN 0003-4932, pages 150 - 154, XP055136010
EXAMINATION- Richard A Ehlers ET AL, "Gut Peptide Receptor Expression in Human Pancreatic Cancers Summary Background Data", Annals of Surgery, (20000101), vol. 231, no. 6, ISSN 0003-4932, pages 838 - 848, XP055136009
EXAMINATION- A. Boulay, "Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer", Clinical Cancer Research, (20050715), vol. 11, no. 14, doi:10.1158/1078-0432.CCR-04-2402, ISSN 1078-0432, pages 5319 - 5328, XP055135782
OPPOSITION- JAMES N. INGLE, Clinical cancer research, (20010600), vol. 7, pages 4392s - 4396s-
OPPOSITION- Public Health England - cell collection HTC116-
OPPOSITION- ANNE BOULAY et al., "Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer", Clin Cancer Res, (20050000), vol. 11, no. 14, XP055135782
SEARCH- GUBA, M. ET AL, "Rapamycin inhibits tumor growth and metastasis by antiangiogenesis", CHIRURGISCHES FORUM FUER EXPERIMENTELLE UND KLINISCHE FORSCHUNG (2001) 37-39, (20010101), XP001088707 [X] 3,5,10 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents